TrialInternational journal of chronic obstructive pulmonary disease2014

Efficacy and safety of olodaterol once daily delivered via Respimat® in patients with GOLD 2-4 COPD: results from two replicate 48-week studies.

Gary T Ferguson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.